BHK-21 cells infected with temperature-sensitive mutants of herpes simplex virus type 1 strain KOS representing 16 complementation groups were tested for susceptibility to complement-mediated immune cytolysis at permissive (340C) and nonpermissive (39°C) temperatures. Only cells infected by mutants in complementation group E were resistant to immune cytolysis in a temperaturesensitive manner compared with wild-type infections. The expression of group E mutant cell surface antigens during infections at 34 and 390C was characterized by a combination of cell surface radioiodination, specific immunoprecipitation, and gel electrophoretic analysis of immunoprecipitates. Resistance to immune lysis at 39°C correlated with the absence of viral antigens exposed at the cell surface. Intrinsic radiolabeling of group E mutant infections with [14C]glucosamine revealed that normal glycoproteins were produced at 34°C but none were synthesized at 390C. The effect of 2-deoxy-D-glucose on glycosylation of group E mutants at 39°C suggested that the viral glycoprotein precursors were not synthesized. The complementation group E mutants failed to complement herpes simplex virus type 1 mutants isolated by other workers. These included the group B mutants of strain KOS, the temperature-sensitive group D mutants of strain 17, and the LB2 mutant of strain HFEM. These mutants should be considered members of herpes simplex virus type 1 complementation group 1.2, in keeping with the new herpes simplex virus type 1 nomenclature.
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It is well established that the surface membranes of cells infected with herpes simplex virus (HSV) contain virus-specified proteins, the majority of which are glycosylated (2, 8-10, 12, 28) . Currently, five terminal glycoprotein species have been identified in both virion envelopes and in infected cell plasma membranes (2, 28) . These proteins have been designated gC, gB, gA, gE, and gD (molecular weights, 129,000, 126,000, 119,000, 83,000, and 59,000, respectively). These glycoproteins appear to be exposed at the surfaces of HSV-infected cells and can be immunoprecipitated with specific antisera (2, 9, 10, 28) . They contain antigenic determinants which are common to the two serotypes of HSV (HSV type 1 [HSV-1] and HSV-2) and determinants which are specific for each serotype (10, 27, 31) . These are referred to as type-common and typespecific antigens and are reactive with crossreactive and type-specific antibodies.
During active infections, herpesvirus-specified cell surface antigens are thought to play a central role in stimulating an immune response in hosts and, in turn, are involved in humoral and cellular immune reactions which destroy infected cells (13, 31) . In vitro studies have shown that HSV cell surface antigens participate in complementmediated (9, 19, 27) and cell-mediated cytotoxicity reactions (18, 19, 25, 26) through specific recognition by cytolytic antibody or immune effector cells. Using a combination of cell surface radioiodination, immunoprecipitation, and polyacrylamide gel electrophoresis, Glorioso and Smith (9) showed that a particular gel region, designated a, contains the majority of immunoprecipitable radioactivity. This region contains HSV glycoproteins having molecular weights in the range 130,000 to 115,000 and appears to contain the glycopeptide species gC, gB, and gA. Both HSV type-specific and cross-reactive antibodies react with antigenic determinants associated with region a plasma membrane glycoproteins and sensitize infected cells to complement-mediated lysis (10) . Recent studies have shown that antisera specific for either gC, gA and gB or gD are cytolytic for HSV-infected cells in both complement-mediated and antibody-dependent cell-mediated immune lysis re- The mutant-infected cells showed a wide range in susceptibility to immune cytolysis. However, only cells infected with our complementation group E mutants were found to be ts for immune cytolysis. These cells were almost completely resistant to immune lysis at 39°C and did not express the major viral glycopeptides in their plasma membranes. These polypeptides were clearly produced at the permissive temperature (34°C). The group E mutants are representatives of the first category described above.
Mutants inducing infections belonging to the other two categories will be discussed in a subsequent paper.
MATERIALS AND METHODS Cells and virus. A continuous line of baby hamster kidney cells (BHK-21) was grown and maintained in 32-ounce (960-ml) glass prescription bottles containing Eagle minimum essential medium (GIBCO Laboratories, Grand Island, N.Y.), nonessential amino acids, and 10% heat-inactivated fetal calf serum (GIBCO), as described previously (1) . Stocks of HSV-1 strain KOS and mutants of strain KOS ts for growth were grown in African green monkey kidney (Vero) cells and titrated by plaque assay on Vero cells (1) . Nine ts mutants, which fell into seven complementation groups (groups A through G [14] ), were kindly supplied by W. Munyon and R. Hughes, Roswell Park Memorial Institute. Also utilized were representative ts mutants from nine other complementation groups (groups H through P), which were isolated in this laboratory. These latter ts mutants were isolated after 5-bromo-2'-deoxyuridine mutagenesis by the method of Hughes and Munyon (14) . These mutants were complemented among themselves and with the mutants in groups A through G by a procedure similar to the quantitative complementation test of Schaffer et al. (22, 23 Antisera. HSV-1 antisera were obtained by intramuscular injection of New Zealand white rabbits with KOS-infected primary rabbit kidney cells (UV inactivated) in complete Freund adjuvant (GIBCO), as described previously (27) . The antisera were heat inactivated at 56°C for 30 min and tested for their ability to lyse KOS-infected cells with added complement. By using the method described by Smith and Glorioso (27) , only sera capable of lysing nearly 100% of the infected cells were used in immune cytolysis assays and for immunoprecipitation of radiolabeled viral antigens. Before use, the antiserum was centrifuged at 50,000 x g for 30 min in a Beckman SW50.1 rotor to remove aggregated antibody molecules.
'1Cr release assay for immune cytolysis. The 5'Cr release assay involving infected cell suspensions (27) Radioiodination of cell surface proteins. Infected cell monolayers were harvested with trypsin and washed three times in Dulbecco phosphatebuffered saline (PBS) (pH 7.0) containing 10,uM KI (PBS-KI); 1 mCi of Na'25I in a solution containing 0.25 ml of 5 ,uM Na2SO3, 0.125 ml of lactoperoxidase (2 mg/ ml), and 0.025 ml of H202 (1.3 mM) in PBS was added to 1.5 ml of PBS-KI containing 2 x 107 cells. Additional H202 was added to the reaction mixture at 2-min intervals, and specific labeling was inhibited after a total of 15 min by the addition of 10 ml of cold PBS-KI. Labeled cells were washed three times with PBS-KI and solubilized in 1 ml of 2% Nonidet P-40 in PBS. After 30 min, the insoluble material was removed by centrifugation for 1 h at 30,000 x g. The supernatant was precipitated with 0.2 ml of heat-inactivated HSV antiserum for 1 h at 37°C, followed by an overnight incubation at 4°C. Immune complexes were pelleted by centrifugation through 20% sucrose containing 0.1% Nonidet P-40 at 50,000 x g for 1 h in a Beckman SW50.1 rotor. The pellet was prepared for electrophoresis by suspension in 0.1 ml of electrophoresis sample solution (ESS) (37.5 mM Tris, pH 7, 5% ,B-mercaptoethanol, 0.25 mg of bromophenol blue per ml, 2% sodium dodecyl sulfate, 20% sucrose) at a final protein concentration of approximately 1 mg/ml; this suspension was placed in a boiling water bath for 5 min.
Intrinsic radiolabeling of viral proteins. BHK cell monolayers in 24-well trays (Costar, Cambridge, Mass.) (2 x 104 cells per well) were infected (multiplicity of infection, 10) with wild-type virus or KOS mutants, and the virus was allowed to absorb for 1 h at the appropriate temperature. Subsequently, the monolayer was overlaid with MEMM, and infected cells were incubated at either 34 or 39°C. At 4 h postinfection, the medium was replaced with MEMM containing either ['4C]glucosamine (3 , uCi/ml) or [35S]methionine (3 yICi/ml) (both from New England Nuclear Corp., Boston, Mass.). Infected cells were harvested with a rubber policeman at 24 h postinfection and pelleted by centrifugation at 100 x g for 10 min. The pellet was suspended in 200 pl of ESS.
Polyacrylamide gel electrophoresis. Immune precipitates or extracts of radiolabeled whole cells were solubiized in ESS and subjected to sodium dodecyl sulfate-polyacrylamide slab gel electrophoresis. Gels (100 by 140 by 1.5 mm) were cast in a model SE 500 slab gel apparatus (Hoefer Scientific Instruments, San Francisco, Calif.). The resolving gel contained 8.5% acrylamide and 0.47% N,N'-diallyltartardiamide, and the stacking gel contained 4% acrylamide and 0.2% N,N'-diallyltartardiamide. Electrophoresis of 20-,I samples was carried out at a constant current of 23 mA/gel by the method of Laemmli (17) . After electrophoresis, gels were fixed for 1 h in an aqueous solution containing 10% acetic acid and 45% methanol (fixer) and stained for 1 h with 0.125% Coomassie brilliant blue dissolved in fixer. Gels were destained with two changes of fixer for 1 h each, followed by two changes of a solution containing 7.5% acetic acid and 5% methanol for 2 h each.
Gels containing electrophoretically separated 35S-or '4C-labeled proteins were prepared for fluorography by the method of Bonner and Laskey (3). Gels were dried on a Hoefer SE 540 slab gel dryer. Dried gels were exposed to Kodak X-Omat R film at -70°C. Gels containing proteins labeled only with 125I were dried directly after destaining and autoradiographed at -70°C on Cronex Xtra Life intensifying screens (DuPont Co., Wilmington, Del.). In each experiment, purified protein standards of known molecular weights (Pharmacia Fine Chemicals, Inc., Piscataway, N.J.) were electrophoresed in parallel with labeled viral proteins for estimation of molecular weights (32) . These standards included ferritin (subunit molecular weight, 220,000), phosphorylase b (94,000), albumin (67,000), catalase (60,000), ovalbumin (43,000), lactate dehydrogenase (36,000), and carbonic anhydrase (30, 000 cells never reached 100%. However, the amount of specific release from infected cells was consistent among experiments and nearly equivalent at the two temperatures (48 and 45%).
Tshe mutants could be divided into three groups on the basis of the response of infected cells to cytolytic antibody. The mutants shown in Fig. 1A released a high percentage of 510r at both 34 and 3900. Therefore, these mutants were not ts for complement-mediated cytolysis. In fact, the cells infected with this group released more5d0r at 3900 than did wild-type-infected cells. ts5-121 exhibited a syncytia-forming phenotype. This phenotype may be the consequence of a second mutation different from the mutation causing growth temperature sensitivity. The fused cells resulting from infection with this mutant appeared to be more fragile than cells infected with a non-syncytia-forming virus. This may account for the increased susceptibility of ts5-121 to cytolytic antibody and complement. The mutants in Fig. lB were somewhat less sensitive to immune cytolysis than wild type. They also were not ts for this character since they gave nearly equivalent amounts of lysis at the two temperatures. The mutants in Fig. 1C gave the most anomalous response to immune cytolysis. All were very resistant at 390C. With the exception of ts-629, they were also resistant at 340C. ts-629 apparently was the only mutant which was ts for immune cytolysis. The susceptibility to lysis of cells infected with this mutant approached that of KOS-infected cells at 3400, but they were not susceptible to lysis at 3900.
Cells infected with ts-606 and ts-756, two other independently isolated mutants in complementation group E, behaved like ts-629-infected cells in immunolysis assays (Fig. 2) .
The level of sensitivity to immune cytolysis could be quantitated more precisely by measuring the effect of antiserum dilution on the amount of immune killing. The serum dilution curves in Fig. 2 also provide data for calculation of 25% killing endpoints, a more quantitative measure of sensitivity to cytolytic antibody and complement ( Table 1 ). The 25% endpoint was the serum dilution required to give 25% 51Cr release from a standard concentration ofinfected cells.
The percentages of 51Cr release at 34 and 390C for wild-type-infected cells were about equal at each serum dilution ( Fig. 2A) , and as expected, the 25% endpoints for wild-type-infected cells were similar at permissive (1:388) and nonpermissive (1:294) temperatures (Table 1 ). This suggests that any differences in lysis of mutantinfected cells are a consequence of the ts mutations and not of the effects of temperature on normal viral polypeptides. Mutant ts-8 and ts-18 infections, which are ts for virus production but not for immune cytolysis, showed wild-type or higher levels of cytolysis at 340C for each dilution of antiserum, giving 25% killing endpoints of 1:446 and 1:388, respectively ( Fig. 2B and C Virus-specific plasma membrane antigens present in wild-type-and mutant-infected cells. Since the complementation group E mutants were very resistant to immune cytolysis at 39°C, it was anticipated that at the nonpermissive temperature these mutants would fail to express those viral glycopeptides which are required to combine with cytolytic antibody at the cell surface. Mutant ts-8, which behaved like wild type, and mutant ts-18, which was moderately resistant to cytolysis at 39°C, were also examined for their expression of viral plasma membrane antigens.
Infected cells were radioiodinated enzymatically by using a lactoperoxidase technique in which only cell surface polypeptides were radiolabeled. Radiolabeled cell surface antigens were solubilized with Nonidet P-40, reacted with HSV-specific antiserum, and pelleted through sucrose. The immunoprecipitates were solubilized in ESS and analyzed by polyacrylamide gel electrophoresis. Figure 3 shows the autoradiogram profiles for '"'I-labeled antigens from wild-type-and mutant-infected cells.
Wild-type-and mutant-infected cells showed similar profiles at 34°C. At In similar experiments, the glycoprotein profiles of ts-18-and ts-8-infected cells were compared with those of the three group E mutants. At 340C, the major viral glycoproteins were labeled in wild-type and all mutant infections (Fig.  5) . At 39°C, however, the three group E mutant infections showed a marked reduction in the synthesis of glycoproteins. At 390C, ts-8 and ts-18 infections showed all of the glycoprotein bands observed at the lower temperature. However, the intensity of the banding with ts-18 was much reduced compared with the intensities with ts-8 and wild type. This decrease in glycoprotein synthesis correlated with a reduction in corresponding viral cell surface antigens and reduced susceptibility to immune cytolysis.
The absence of glycoproteins in the nonpermissive infections with the group E mutants could have been due to a failure to synthesize the glycoprotein precursors or to a defect in the glycosylation of these precursors. The mannose analog 2-deoxy-D-glucose blocks glycosylation of HSV-1 proteins, resulting in an accumulation of lower-molecular-weight polypeptides and an absence of the terminal glycoprotein species (5, 16) . These accumulating polypeptides are presumably precursor forms of the mature viral glycoproteins. To determine whether the group 1231i I KOS ts629 1 Whole ceU extracts were prepared in ESS and electrophoresed inparallel with '25I-labeledproteins. 121I
labeled and '4C-labeledproteins separated in sodium dodecyl sulfate-polyacrylamide slab gels were visualized by fluorography. Molecular weights (x103) are shown on the right and left.
E mutants were defective in glycosylation or in the production of glycoprotein precursors, mockinfected, KOS-infected, and ts-606-infected cells were labeled with [35S]methionine in the presence and absence of 10 mM 2-deoxy-D-glucose at 34 and 390C and examined by polyacrylamide gel electrophoresis for the synthesis of precursor and fully glycosylated polypeptides. The analog was present from 5 to 24 h after infection.
As k' 0i ts < R X e t s t I f. rjf t S62 P;.
permissive temperature (6, 7, 21, 24 (6, 7, 21) . Previously, all of these proteins have been reported to be nonstructural proteins (6, 7, 21 Three independently arising group E mutants, ts-606, ts-629, and ts-756, were examined in these studies, and all behaved similarly, suggesting that the phenotype of these mutants is characteristic of the mutant gene. Cells infected with the three mutants are completely resistant to complement-mediated immune cytolysis at 39°C. The resistance is not due to the absence of a specific antigen, but rather to the absence of a whole set of antigens which are normally introduced into cell surface membranes during infection. These viral antigens cannot be detected on nonpermissively infected cell surfaces by cell surface labeling procedures followed by immunoprecipitation. The failure to synthesize cell surface antigens in group E mutant-infected cells is probably not directly related to the DNAnegative phenotype of the mutants. ts-8 and ts-18 also show DNA-negative phenotypes (unpublished data), but cells infected with these mutants synthesize normal or near normal amounts of virus proteins and show normal or near normal levels of complement-mediated cytolysis.
The precise function governed by the group E locus is not known. The defect appears not to be in the glycosylation process itself, but rather in the synthesis of the peptide precursors. Courtney (5) (6, 7, 20, 21 (4) and the ts-LB2 mutant of strain HFEM (11) . Finally, the latter two mutants fail to complement each other in mixed infections (15) . In keeping with the new HSV-1 nomenclature proposed by Schaffer et al. (23) , these mutants should be considered members of HSV-1 complementation group 1.2. Nonpermissive infections with these mutants are DNA negative, and a large number of late proteins are not observed (4, 6, 7, 11) . Dixon and Schaffer (unpublished data) have confirmed our finding with their group B mutants, namely, that mutant-infected cells fail to produce viral glycoproteins. Marker rescue and intertypic recombination experiments physically map these mutations in the S region of the viral genome (15, 29, 30 ; D. Parris, R. Dixon, and P. Schaffer, unpublished data; R. Sandri, M. Levine, and J. C. Glorioso, unpublished data). A recent report (21) describes the characteristics of the ts K mutant of HSV-1 strain 17. This mutant has a phenotype similar to that of the group 1.2 mutants. Immediate early proteins are made under nonpermissive conditions, but late proteins are not. The mutation also maps in the S segment of the virus genome (29, 30) .
Results from this study demonstrate that the resistance of group E mutant infections to complement-mediated immune lysis is correlated with the absence of viral cell surface antigens. To date, there has been no evidence to suggest that the presence of any one particular surface antigen is essential for complement-mediated immune lysis. It is possible that many of these antigens can participate in immune lysis reactions, provided that specific cytolytic antibodies are present (9, 10, 19) . Specific lesions in viral cell surface antigen expression have been found in analyses of other ts mutants of strain KOS (J. C. Glorioso, T. C. Holland, and M. Levine, unpublished data). The role of these specific peptides in the immune response to HSV-1 infections is currently under investigation. The group E mutants continue to be useful in these studies as mutants representing one end of the spectrum of variants in viral cell surface antigen expression. The group E mutants will also be useful in studies on the control of glycoprotein synthesis in infected cells.
